In some cases, the only time a company reveals important developments is during their quarterly earnings calls. This past “earnings season” also yielded a few interesting tidbits. The first notes relate to the adalimumab market, as reported by the manufacturers. First, AbbVie disclosed that third-quarter net sales of Humira in the US were down 42% … Continue reading Third-Quarter Earnings News and Biosimilar Revenues